The announcement is intriguing but incomplete. As DeepMind's blog post lays it out, Co-Scientist's ability to identify repurposed drugs like vorinostat is impressive, but the research is still in early stages. The leap from lab experiments to clinical efficacy is vast, and the tool's broader applicability across other diseases remains untested.
The emphasis on reshaping gene activity raises questions about potential side effects and long-term safety. The AI's success here doesn't guarantee similar breakthroughs elsewhere, and its reliance on existing literature may limit its ability to propose truly novel therapies.
The real test will be whether these findings translate into scalable, affordable treatments for patients. Until then, this remains a promising but cautious step forward.